Which Maintenance Option Suits Your UK Lifestyle?
Wegovy Maintenance Dose vs Mounjaro: The UK Clinical Landscape
After achieving your target weight with Wegovy, the question of long-term maintenance becomes crucial for UK patients. The Wegovy maintenance dose of 2.4mg weekly represents the maximum licensed strength, designed to sustain appetite suppression and weight management benefits. However, some patients explore switching to Mounjaro (tirzepatide), which offers a different mechanism targeting both GLP-1 and GIP receptors. This dual-pathway approach may provide alternative benefits for certain individuals, though any transition requires careful medical supervision and cannot be done directly—patients must typically discontinue one treatment before starting another.
The maintenance phase presents unique challenges that differ from the initial weight loss journey. Whilst Wegovy maintenance dose protocols in the UK follow established STEP trial frameworks, Mounjaro offers six different dose levels (2.5mg to 15mg) compared to Wegovy's five doses (0.25mg to 2.4mg). This flexibility means some patients may find Mounjaro's dosing range better suits their individual tolerance and maintenance needs. Both treatments remain prescription-only medicines requiring ongoing clinical oversight, particularly during any maintenance strategy adjustments.
Wegovy Maintenance Dose Pricing vs Mounjaro Cost Analysis UK
Understanding the financial commitment for long-term maintenance helps UK patients plan their weight management journey effectively. Wegovy's 2.4mg maintenance dose costs £209.99 per pen at EverydayMeds, whilst our Ultimate Stability Trio provides three months of 2.4mg supply for £649.99—offering convenience and supply security. New customers benefit from discount code FIRST40, whilst returning patients use DOSE25 at checkout to access these competitive prices. The Getting Started journey through lower doses costs progressively less, with 0.25mg starting at £79.99, making the escalation pathway financially manageable.
Mounjaro pricing follows a different structure, reflecting its distinct dosing schedule and dual-mechanism formulation. Direct cost comparisons depend on individual maintenance requirements, as some patients may require higher or lower Mounjaro doses compared to Wegovy's standard 2.4mg maintenance. Both treatments qualify for the same prescription assessment process through our GPhC-registered service (#9012878), ensuring equivalent clinical oversight regardless of your chosen maintenance strategy. Bundle options for both medications provide supply continuity, particularly important during ongoing maintenance phases where treatment interruptions can affect weight stability.
Clinical Evidence: Wegovy Maintenance Dose Outcomes vs Mounjaro Trials
The STEP trial programme demonstrates Wegovy maintenance dose effectiveness over extended periods, with STEP 5 showing sustained weight management at 2 years when patients continued their 2.4mg weekly injections. In clinical trials, patients taking Wegovy alongside diet and exercise maintained approximately clinically studied weight loss from baseline, though individual results varied significantly. The STEP 1 extension study revealed that discontinuation led to weight regain of approximately two-thirds within one year, highlighting the importance of consistent maintenance dosing.
Mounjaro's clinical evidence comes from the SURMOUNT trial series, showing different efficacy patterns due to its dual GLP-1/GIP mechanism, though direct comparison with Wegovy trials isn't methodologically appropriate due to different study designs. Both medications demonstrate the principle that weight management requires long-term commitment, with maintenance phases being as crucial as initial weight loss periods. The choice between Wegovy maintenance dose continuation or Mounjaro transition should consider individual response patterns, tolerability, and practical factors like storage requirements.
How Wegovy Maintenance Dose Mechanisms Compare to Mounjaro
Wegovy's maintenance effectiveness relies on sustained GLP-1 receptor activation, mimicking natural incretin hormones that regulate appetite and gastric emptying. The 2.4mg maintenance dose provides consistent receptor occupancy throughout the week, maintaining the appetite suppression and satiety enhancement that characterised your initial weight loss phase. This single-pathway approach offers predictable pharmacology, with well-established dose-response relationships documented through extensive clinical use. Mounjaro's dual-pathway activation of both GLP-1 and GIP receptors may provide additional metabolic benefits beyond appetite control, potentially affecting insulin sensitivity and fat metabolism differently than Wegovy's GLP-1-only mechanism. However, this complexity means individual responses can be less predictable, requiring careful monitoring during any transition from Wegovy maintenance protocols.
UK Ordering Process: Wegovy Maintenance Dose vs Mounjaro Assessment
Accessing either Wegovy maintenance doses or Mounjaro through EverydayMeds follows our streamlined 3-minute online clinical assessment, designed to evaluate your current weight management status and treatment history. Our prescribers, available for standard review within 3 working days or express 24-hour service, assess your suitability for continued Wegovy maintenance or potential Mounjaro transition based on your individual circumstances and previous treatment response. The assessment considers factors like current weight stability, any side effects experienced, and practical considerations such as injection preferences and storage capabilities. Once approved, both treatments receive next-day delivery through our temperature-controlled cold-chain system, ensuring medication integrity throughout the UK. This process maintains continuity whether you're refilling Wegovy maintenance doses or exploring Mounjaro as an alternative maintenance strategy.
Storage Advantages: Wegovy Maintenance Dose vs Mounjaro Practicality UK
Storage requirements significantly impact long-term maintenance success, particularly for UK patients with active lifestyles or frequent travel commitments. Wegovy offers superior storage flexibility with 6 weeks room temperature tolerance below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit—a crucial advantage for business travel or holiday periods. Both treatments require initial refrigerated storage at 2-8°C, but Wegovy's extended room temperature stability provides greater peace of mind for maintenance patients who may face storage challenges. The FlexTouch pen delivery system used by Wegovy features robust construction and reliable dose accuracy, whilst both treatments utilise similar injection techniques with fine-gauge needles. This storage advantage often influences maintenance treatment choice, especially for patients requiring consistent weekly dosing without refrigeration access during extended periods away from home.
Wegovy Maintenance Dose Transition Strategies vs Mounjaro Switch Protocols UK
Transitioning between maintenance strategies requires careful medical supervision, as direct switching from Wegovy maintenance dose to Mounjaro isn't typically recommended without a washout period. Patients considering this change usually discontinue Wegovy first, allowing clearance of semaglutide before commencing Mounjaro at its lowest dose (2.5mg), then escalating according to standard protocols. This process means temporary interruption of weight management medication, which may affect weight stability during the transition period. Some patients prefer to optimise their current Wegovy maintenance dose first, exploring factors like injection timing, dietary coordination, and lifestyle modifications before considering alternative treatments.
The decision between continuing Wegovy maintenance versus exploring Mounjaro depends on individual factors including treatment response, side effect profile, and personal preferences regarding dosing flexibility. Both approaches require ongoing commitment to reduced-calorie diet and increased physical activity, with regular monitoring through appropriate healthcare channels. EverydayMeds supports both pathways through our clinical team, ensuring patients receive appropriate guidance regardless of their chosen maintenance strategy while maintaining compliance with MHRA licensing requirements.
Expert UK Guidance: Choosing Your Wegovy Maintenance Dose vs Mounjaro Path
Making informed decisions about long-term weight maintenance requires understanding both the clinical evidence and practical implications of each treatment option. Our GPhC-registered clinical team (#9012878) provides comprehensive support throughout your maintenance journey, whether continuing with proven Wegovy 2.4mg maintenance or exploring Mounjaro's alternative mechanism. Both treatments remain prescription-only medicines requiring ongoing medical oversight, with regular assessments ensuring optimal outcomes and safety monitoring. Access both options through our secure online platform at https://everydaymeds.co.uk/collections/weight-loss, where new customers can apply discount code FIRST40 and returning patients use DOSE25 for competitive pricing. Remember that successful weight maintenance represents a long-term commitment, and the right treatment choice depends on your individual circumstances, preferences, and clinical response pattern under professional medical guidance.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
